Bristol-Myers Squibb (BMY) - Get Report and Sanofi-Aventis (SNY) - Get Report won a preliminary injunction to stop generic-drug maker Apotex from selling a generic version of their Plavix heart pill, the world's second-biggest selling medicine.

Bloomberg

reported late Thursday that U.S. District Court Judge Sidney H. Stein ruled that Bristol-Myers and Sanofi are likely to win their patent-infringement suit against Apotex and wouldn't be able to recoup losses if generic sales were continued.

The injunction will remain in effect until the patent suit in New York concludes or Apotex wins an appeal. The lawsuit is scheduled for trial in January,

Bloomberg

said.

Stein denied the companies' request to force Apotex to recall the drugs it has sold to U.S. distributors and drugstores.

Apotex has captured more than half of U.S. prescriptions for Plavix since it began selling the generic version on Aug. 8, according to industry analysts cited by

Bloomberg

. Plavix had U.S. sales of $3.8 billion last year.

Shares of Bristol-Myers rose $1.45, or 6.7%, to $23.20 on Instinet in after-hours trading.